Jump Financial LLC Sells 68,025 Shares of Incyte Co. (NASDAQ:INCY)

Jump Financial LLC reduced its holdings in Incyte Co. (NASDAQ:INCYFree Report) by 91.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,983 shares of the biopharmaceutical company’s stock after selling 68,025 shares during the quarter. Jump Financial LLC’s holdings in Incyte were worth $346,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. State of Alaska Department of Revenue lifted its holdings in Incyte by 13.6% during the 3rd quarter. State of Alaska Department of Revenue now owns 64,309 shares of the biopharmaceutical company’s stock worth $3,714,000 after buying an additional 7,695 shares in the last quarter. Seven Eight Capital LP acquired a new stake in shares of Incyte in the 2nd quarter valued at about $6,311,000. Dimensional Fund Advisors LP raised its stake in shares of Incyte by 12.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 845,484 shares of the biopharmaceutical company’s stock valued at $52,629,000 after purchasing an additional 92,894 shares during the period. Cibc World Markets Corp raised its stake in shares of Incyte by 131.8% in the 2nd quarter. Cibc World Markets Corp now owns 21,691 shares of the biopharmaceutical company’s stock valued at $1,350,000 after purchasing an additional 12,333 shares during the period. Finally, Empirical Finance LLC raised its stake in shares of Incyte by 13.1% in the 2nd quarter. Empirical Finance LLC now owns 5,801 shares of the biopharmaceutical company’s stock valued at $361,000 after purchasing an additional 674 shares during the period. Institutional investors and hedge funds own 92.61% of the company’s stock.

Incyte Trading Up 0.3 %

Shares of NASDAQ:INCY opened at $57.84 on Tuesday. Incyte Co. has a 12-month low of $50.27 and a 12-month high of $80.22. The stock has a market cap of $12.96 billion, a PE ratio of 30.60, a P/E/G ratio of 0.63 and a beta of 0.67. The business has a 50 day moving average of $61.09 and a 200-day moving average of $59.80. The company has a quick ratio of 3.86, a current ratio of 3.91 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling at Incyte

In related news, EVP Vijay K. Iyengar sold 657 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $65.00, for a total value of $42,705.00. Following the sale, the executive vice president now owns 43,412 shares of the company’s stock, valued at $2,821,780. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 17.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on INCY shares. Truist Financial reissued a “buy” rating and issued a $91.00 price target on shares of Incyte in a research note on Wednesday, November 29th. StockNews.com raised Incyte from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 1st. Mizuho lowered their target price on Incyte from $82.00 to $77.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. The Goldman Sachs Group downgraded Incyte from a “buy” rating to a “neutral” rating and lowered their target price for the company from $98.00 to $65.00 in a research report on Tuesday, November 21st. Finally, Guggenheim raised Incyte from a “neutral” rating to a “buy” rating and set a $86.00 target price on the stock in a research report on Monday, December 4th. Eight research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $78.67.

View Our Latest Stock Report on INCY

Incyte Profile

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Recommended Stories

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYFree Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.